Stay updated with breaking news from Trappsol Cyclo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 41 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it contrast to its competitors? We will compare Cyclo Therapeutics to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership. Analyst Ratings This is a […]
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 41 public companies in the “Industrial organic chemicals” industry, but how does it contrast to its competitors? We will compare Cyclo Therapeutics to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership. Insider and Institutional Ownership 5.2% […]
Success in the treatment of Alzheimer's disease likely requires specific antioxidants like Anavex's (AVXL) Anavex 2-73, Cyclo, and GV-971. Read more here.
Most treatments for Alzheimer's disease either lead to only temporary improvements or only minimally slow down the progression of the disease. Read what makes investors positive on Anavex...
No Headlines Available Cyclo Therapeutics Inc. Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL. ...